Karyopharm to present new data on pomalyst, SPd arm in Phase 1b/2 STOMP study
Karyopharm Therapeutics announced three presentations highlighting new and updated data from the Phase 1b/2 STOMP study evaluating selinexor, the company's first-in-class, oral Selective Inhibitor of Nuclear Export compound, and dexamethasone in combination with standard approved multiple myeloma therapies, Kyprolis Darzalex, or Pomalyst, in patients with previously treated multiple myeloma. Selinexor plus Pomalyst and Low-dose Dexamethasone: In this arm of the Phase 1b/2 STOMP study, oral selinexor is being evaluated in combination with Pomalyst and low dose dex in patients with relapsed or refractory MM who received at least two prior lines of therapy, including a PI and an IMiD, or patients with MM refractory to both a PI and an IMiD. Among the 45 patients evaluated for safety as of the data cutoff date, the most common treatment-related AEs were cytopenias, along with gastrointestinal and constitutional symptoms; most manageable with dose modifications and/or standard supportive care. The most common non-hematologic treatment-related AEs were nausea, fatigue and anorexia and mostly Grade 1 and 2 events. As expected, the most common treatment-related Grade 3 and 4 AEs were hematologic AEs and included neutropenia, thrombocytopenia, anemia and leukopenia. There were three Grade 5 treatment-related events. Determination of the RP2D is still ongoing.